N-tosyl-L-phenylalanine chloromethyl ketone inhibits LHRH-degrading activity and increases in vitro LHRH release from the immature rat median eminence.
Median eminence (ME) luteinizing-hormone-releasing hormone (LHRH)-degrading activity (LHRH-DA) may play a role in regulating the availability of releasable LHRH. Incubation of LHRH with ME tissue supernatant yields LHRH(1-5) and LHRH(6-10) degradation fragments, as detected by high-performance liquid chromatography (HPLC) analysis, suggesting a 5-6 cleavage of the decapeptide. Since these fragments are also present after incubation of LHRH with alpha-chymotrypsin (alpha-CH), we examined the possibility that the irreversible inhibitor of alpha-CH, N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), might inhibit LHRH-DA and affect LHRH release. Irreversible inhibitors of trypsin-like proteases [N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK), and phenylmethylsulfonylfluoride (PMSF)] were used as controls. LHRH-DA was determined by HPLC estimation of the loss of synthetic LHRH incurred when the peptide was incubated with aliquots of ME supernatant in the presence or absence of the inhibitors. LHRH release from ME fragments was assessed by radioimmunoassay after incubating the tissue with the inhibitors in Krebs-Ringer bicarbonate buffer. The LHRH-DA in both the incubation medium and the ME tissue was determined at the end of the incubation. TPCK (0.5-100 microM) added to ME tissue supernatant inhibited LHRH-DA in a dose-dependent manner. In contrast, when TPCK was added to medium in which intact ME were being incubated to assess LHRH release, the LHRH-DA of these ME was inhibited only at the 25-, 50- and 100-microM doses of TPCK, suggesting a relative inability of the inhibitor to reach endopeptidase pools in intact tissue. These same doses of TPCK increased LHRH release from the incubated ME.(ABSTRACT TRUNCATED AT 250 WORDS)
Advis
J P
JP
Department of Animal Sciences, Rutgers University, New Brunswick, N.J.
Contijoch
A M
AM
Urbanski
H F
HF
Ojeda
S R
SR
D000367:Age Factors; D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology*; D000818:Animals; D015232:Dinoprostone; D010450:Endopeptidases / Q000378:metabolism*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism*; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008473:Median Eminence / Q000187:drug effects / Q000201:enzymology*; D009638:Norepinephrine / Q000494:pharmacology; D011458:Prostaglandins E / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D014108:Tosylphenylalanyl Chloromethyl Ketone / Q000494:pharmacology*
D000590:Amino Acid Chloromethyl Ketones; D011458:Prostaglandins E; D007987:Gonadotropin-Releasing Hormone; D014108:Tosylphenylalanyl Chloromethyl Ketone; D010450:Endopeptidases; D015232:Dinoprostone; D009638:Norepinephrine; D007213:Indomethacin